Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Atai Life Sciences (ATAI) stocks

Learn how to easily invest in Atai Life Sciences stocks.

Atai Life Sciences, a Peter Thiel-backed company that produces psychedelic and non-psychedelic mushroom-based therapies for depression and anxiety, is now publicly available on the Nasdaq. Read on to learn how to buy Atai Life Sciences from Canada.

How to buy Atai Life Sciences stock

  1. Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds unto your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – ATAI. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Promoted for Beginners

Promoted

National Bank Direct Brokerage


  • Commission-free trading
  • Several account types available
  • Access to array of research tools

Promoted for Low Fees

CIBC Investor's Edge


  • Easy to use platform
  • Low fees
  • Student and young investor discounts

Best for Lowest Commissions

Finder Award

Interactive Brokers


  • Access to international stock exchanges
  • Low margin rates
  • Powerful research tools

Atai Life Sciences stock price (NASDAQ:ATAI)

Use our graph to track the performance of ATAI stocks over time.

Atai Life Sciences shares at a glance

Information last updated 2023-05-27.
Latest market close$1.77
52-week range$1.14 - $4.96
50-day moving average $1.79
200-day moving average $2.60
Wall St. target price$13.15
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-0.89

Buy Atai Life Sciences stocks from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Note: The dollar amounts in the table below are in Canadian dollars.

1 - 5 of 5
Name Product Finder Rating Available Asset Types Stock Trading Fee Account Fee Signup Offer Table description
National Bank Direct Brokerage
Finder Rating:
★★★★★
4.2 / 5
Stocks, Bonds, Options, Mutual Funds, GICs
$0
$0 if conditions met, or $100
Get $0 commission on all transactions with promo code: finder
CIBC Investor's Edge
Finder Rating:
★★★★★
3.8 / 5
Stocks, Bonds, Options, Mutual Funds, ETFs
$4.95–$6.95
$0 if conditions met, or $100
N/A
An easy-to-use platform with access to a variety of tools to help you trade with confidence.
Interactive Brokers
Finder Rating:
★★★★★
4.3 / 5
Stocks, Bonds, Options, ETFs, Currencies, Futures
min $1.00, max 0.5%
$0
N/A
Winner for Best Overall Broker in the Finder Stock Trading Platform Awards.
Questrade
Finder Rating:
★★★★★
4.3 / 5
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
$4.95 - $9.95
$0
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio to take out some of the guesswork.
Qtrade Direct Investing
Finder Rating:
★★★★★
3.7 / 5
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Get up to $150 sign-up bonus. Use promo code BONUS150. Conditions apply. Ends June 30, 2023.
Low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options.
loading

Is it a good time to buy Atai Life Sciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Atai Life Sciences price performance over time

Historical closes compared with the close of $1.77 from 2023-05-26

1 week (2023-05-19) -5.85%
1 month (2023-04-28) -7.33%
3 months (2023-02-28) 5.36%
6 months (2022-11-25) -42.72%
1 year (2022-05-25) -53.91%
2 years (2021-05-24) N/A
3 years (2020-05-24) N/A
5 years (2018-05-24) N/A
[/expander_content] [/expander]

Atai Life Sciences financials

Revenue TTM $233,000
Gross profit TTM $233,000
Return on assets TTM -25.09%
Return on equity TTM -48.31%
Profit margin 0%
Book value $1.57
Market capitalisation $293.8 million

TTM: trailing 12 months

Atai Life Sciences share dividends

We're not expecting Atai Life Sciences to pay a dividend over the next 12 months.

Atai Life Sciences overview

Atai Life Sciences N. V. , through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA neurotransmitter systems to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the anxiety-related disorder treatment; and Neuronasal, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01 for TRD; and KUR-101, a formulation of deuterated mitragynine to treat OUD. The company was formerly known as Adripa Holding B.

Frequently asked questions


Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Ask an Expert

You must be logged in to post a comment.

Go to site